禾迈股份(688032)研发投入分析:技术领先性能否维持?
Unlock More Features
Login to access AI-powered analysis, deep research reports and more advanced features

About us: Ginlix AI is the AI Investment Copilot powered by real data, bridging advanced AI with professional financial databases to provide verifiable, truth-based answers. Please use the chat box below to ask any financial question.
Related Stocks
首先需要指出的是,
| 年份 | 营业收入(亿元) | 研发费用(亿元) | 研发费用率(%) | 研发费用同比增长(%) |
|---|---|---|---|---|
| 2020 | 4.95 | 0.29 | 5.86% | - |
| 2021 | 7.95 | 0.46 | 5.79% | 58.55% |
| 2022 | 15.37 | 0.97 | 6.31% | 112.75% |
| 2023 | 20.26 | 2.48 | 12.24% |
154.36% |
| 2024 | 19.93 | 2.66 | 13.35% |
7.41% |
- 2024年研发费用率达13.35%,较2020年提升7.49个百分点
- 研发费用5年CAGR高达74.24%
- 2023年起研发投入显著加速,费用率翻倍增长
| 企业 | 2024年研发费用率 | 研发费用(亿元) |
|---|---|---|
禾迈股份 |
13.35% |
2.66 |
| 锦浪科技 | 6.67% | 4.85 |
| 阳光电源 | 3.71% | 30.12 |
| 行业平均 | 5.4% | - |
禾迈股份的研发费用率在行业中处于
根据公开信息,禾迈股份在技术研发方面展现出以下优势[1]:
- 专利数量:拥有300多项全球专利及软件著作权
- 核心技术:多项填补国内外行业空白的核心技术
- 研发实验室:获得CSA Group、TÜVNORD、BUREAU VERITAS等国际权威检测机构认可
- 技术方向:在高转换效率、高功率密度、高可靠性和低成本等方面持续突破
禾迈股份专注于
- 短期(1-2年):高研发投入(13.35%费用率)和丰富的专利储备能够支撑技术领先优势
- 中期(2-3年):需关注研发成果转化效率,以及如何应对竞争对手的追赶
- 长期(3年以上):取决于技术迭代能力和市场拓展成效
建议持续关注公司研发投入产出比、新产品推出进度以及市场份额变化情况。
[0] 金灵API财务数据
[1] 搜狐 - 杭州禾迈电力电子获国家级博士后工作站批准 (https://www.sohu.com/a/866204718_121798711)
[2] 证券之星 - 禾迈股份获得外观设计专利授权 (http://stock.stockstar.com/RB2025030800056134.shtml)
[3] 南方财富网 - 逆变器10强排行榜 (http://www.southmoney.com/gupiao/sjjh/202502/56766476.html)
再鼎医药ZL-1310肿瘤管线价值评估
Insights are generated using AI models and historical data for informational purposes only. They do not constitute investment advice or recommendations. Past performance is not indicative of future results.
About us: Ginlix AI is the AI Investment Copilot powered by real data, bridging advanced AI with professional financial databases to provide verifiable, truth-based answers. Please use the chat box below to ask any financial question.